Sippican Capital Advisors grew its holdings in Organon & Co. (NYSE:OGN - Free Report) by 138.7% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 36,352 shares of the company's stock after acquiring an additional 21,122 shares during the quarter. Sippican Capital Advisors' holdings in Organon & Co. were worth $542,000 as of its most recent SEC filing.
Other institutional investors and hedge funds have also modified their holdings of the company. Barclays PLC raised its position in shares of Organon & Co. by 238.0% in the 3rd quarter. Barclays PLC now owns 119,483 shares of the company's stock valued at $2,285,000 after buying an additional 84,136 shares in the last quarter. Weiss Asset Management LP acquired a new position in Organon & Co. during the third quarter valued at approximately $32,966,000. Cerity Partners LLC raised its position in Organon & Co. by 94.0% during the third quarter. Cerity Partners LLC now owns 667,340 shares of the company's stock valued at $12,766,000 after purchasing an additional 323,308 shares in the last quarter. Foundry Partners LLC bought a new stake in Organon & Co. during the third quarter worth $7,642,000. Finally, Beddow Capital Management Inc. boosted its holdings in shares of Organon & Co. by 38.8% in the 3rd quarter. Beddow Capital Management Inc. now owns 306,675 shares of the company's stock valued at $5,867,000 after purchasing an additional 85,775 shares in the last quarter. 77.43% of the stock is currently owned by institutional investors and hedge funds.
Wall Street Analysts Forecast Growth
Separately, TD Cowen raised Organon & Co. to a "hold" rating in a report on Wednesday, January 15th. One analyst has rated the stock with a sell rating, two have issued a hold rating, one has assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Hold" and an average price target of $21.33.
Read Our Latest Stock Analysis on Organon & Co.
Organon & Co. Price Performance
Organon & Co. stock traded down $0.60 during mid-day trading on Monday, reaching $14.97. The company had a trading volume of 2,188,201 shares, compared to its average volume of 2,530,619. The business has a fifty day simple moving average of $15.47 and a 200 day simple moving average of $17.89. The company has a market cap of $3.85 billion, a P/E ratio of 2.96, a P/E/G ratio of 0.87 and a beta of 0.76. Organon & Co. has a fifty-two week low of $13.87 and a fifty-two week high of $23.10. The company has a current ratio of 1.70, a quick ratio of 1.21 and a debt-to-equity ratio of 17.73.
Organon & Co. (NYSE:OGN - Get Free Report) last issued its quarterly earnings data on Thursday, October 31st. The company reported $0.87 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.90 by ($0.03). Organon & Co. had a net margin of 20.30% and a return on equity of 644.70%. The business had revenue of $1.58 billion during the quarter, compared to the consensus estimate of $1.56 billion. During the same quarter last year, the business earned $0.78 EPS. The firm's quarterly revenue was up 4.1% compared to the same quarter last year. On average, equities research analysts predict that Organon & Co. will post 3.82 earnings per share for the current year.
Organon & Co. Company Profile
(
Free Report)
Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women's health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.
Further Reading

Before you consider Organon & Co., you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Organon & Co. wasn't on the list.
While Organon & Co. currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.